Global Hormone Replacement Therapy Market Share

Statistics for the 2023 & 2024 Global Hormone Replacement Therapy market share, created by Mordor Intelligence™ Industry Reports. Global Hormone Replacement Therapy share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Hormone Replacement Therapy Industry

The market is moderately competitive, with few major players dominating the market globally. The key companies are Abbott Laboratories, Bayer AG, Merck KGaA, Novartis AG, and Pfizer Inc. However, there are efforts being made by new players to enter the hormone replacement therapy market. Additionally, the key players are focused on global product portfolio expansion through acquisitions and collaborations with companies that complement their portfolios. For instance, in December 2020, the US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, along with an additional approval as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Hormone Replacement Therapy (HRT) Market Leaders

  1. Abbott Laboratories

  2. Novartis AG

  3. Pfizer Inc.

  4. Merck KGaA

  5. Bayer AG

*Disclaimer: Major Players sorted in no particular order

Hormone Replacement Therapy Market Concentration

Hormone Replacement Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)